Please wait while the formulary information is being retrieved.
Drug overview for OBAGI NU-DERM (oxybenzone/octinoxate/hydroquinone):
Generic name: OXYBENZONE/OCTINOXATE/HYDROQUINONE (hi-dro-KWIN-own/sunscreen)
Drug class:
Therapeutic class: Dermatological
Hydroquinone, which is structurally related to monobenzone, is a depigmenting agent.
No enhanced Uses information available for this drug.
Generic name: OXYBENZONE/OCTINOXATE/HYDROQUINONE (hi-dro-KWIN-own/sunscreen)
Drug class:
Therapeutic class: Dermatological
Hydroquinone, which is structurally related to monobenzone, is a depigmenting agent.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for OBAGI NU-DERM (oxybenzone/octinoxate/hydroquinone) have been approved by the FDA:
Indications:
Dyschromia
Facial hyperpigmentation
Professional Synonyms:
Anomalous pigmentation of the skin
Discoloration of skin
Discolored skin
Hyperpigmentation of the face
Pigmentation alteration
Skin pigmentation disorder
Indications:
Dyschromia
Facial hyperpigmentation
Professional Synonyms:
Anomalous pigmentation of the skin
Discoloration of skin
Discolored skin
Hyperpigmentation of the face
Pigmentation alteration
Skin pigmentation disorder
The following dosing information is available for OBAGI NU-DERM (oxybenzone/octinoxate/hydroquinone):
To depigment hyperpigmented skin, a thin layer of hydroquinone cream or solution should be applied uniformly and rubbed into the pigmented area twice daily, in the morning and evening. Application of the drug should be limited to an area equal to that of the face and neck or hands and arms. Exposure to sunlight should be minimized during treatment (See Cautions: Precautions and Contraindications); the opaque base in some hydroquinone preparations (Eldopaque(R), Eldopaque Forte(R)) may provide sufficient protection from sunlight.
If no depigmentation is evident after 2 months of hydroquinone treatment, the drug should be discontinued. When the desired degree of depigmentation is obtained, hydroquinone should be applied only as often as needed to maintain depigmentation.
If no depigmentation is evident after 2 months of hydroquinone treatment, the drug should be discontinued. When the desired degree of depigmentation is obtained, hydroquinone should be applied only as often as needed to maintain depigmentation.
Preparations containing 2-4% hydroquinone are applied topically. Hydroquinone should not be administered orally.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| OBAGI NU-DERM SUNFADER | Maintenance | Adults apply a thin layer to the affected area(s) by topical route 2 times per day |
No generic dosing information available.
The following drug interaction information is available for OBAGI NU-DERM (oxybenzone/octinoxate/hydroquinone):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for OBAGI NU-DERM (oxybenzone/octinoxate/hydroquinone):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 1 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Sunburn |
There are 0 moderate contraindications.
The following adverse reaction information is available for OBAGI NU-DERM (oxybenzone/octinoxate/hydroquinone):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 8 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Contact dermatitis Hypersensitivity drug reaction |
| Rare/Very Rare |
|---|
|
Acne vulgaris Contact dermatitis Dyschromia Folliculitis Skin irritation Skin rash |
There are 1 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Dry skin |
None. |
| Rare/Very Rare |
|---|
| None. |
The following precautions are available for OBAGI NU-DERM (oxybenzone/octinoxate/hydroquinone):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Reproductive studies in animals have not been performed with topical hydroquinone. It is not known whether hydroquinone can cause fetal harm when used topically by pregnant women. Topical hydroquinone should be used during pregnancy only when clearly needed.
Since it is not known if topical hydroquinone is absorbed or distributed into human milk, the drug should be used with caution in nursing women.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for OBAGI NU-DERM (oxybenzone/octinoxate/hydroquinone):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for OBAGI NU-DERM (oxybenzone/octinoxate/hydroquinone)'s list of indications:
| Dyschromia | |
| L81.9 | Disorder of pigmentation, unspecified |
| Facial hyperpigmentation | |
| H02.71 | Chloasma of eyelid and periocular area |
| H02.711 | Chloasma of right upper eyelid and periocular area |
| H02.712 | Chloasma of right lower eyelid and periocular area |
| H02.713 | Chloasma of right eye, unspecified eyelid and periocular area |
| H02.714 | Chloasma of left upper eyelid and periocular area |
| H02.715 | Chloasma of left lower eyelid and periocular area |
| H02.716 | Chloasma of left eye, unspecified eyelid and periocular area |
| H02.719 | Chloasma of unspecified eye, unspecified eyelid and periocular area |
| L81.0 | Postinflammatory hyperpigmentation |
| L81.1 | Chloasma |
| L81.3 | Cafe au lait spots |
| L81.4 | Other melanin hyperpigmentation |
| L81.8 | Other specified disorders of pigmentation |
| L81.9 | Disorder of pigmentation, unspecified |
Formulary Reference Tool